On Thursday, Liquidia got an upgrade to its Relative Strength (RS) Rating, from 88 to 91.
Here Are 3 Keys For Successful Stock Investing
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Liquidia is now considered extended and out of buy range after clearing a 16.81 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 5%. The company is expected to report its latest results on or around Aug. 7.
The company holds the No. 169 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Harmony Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
